|
1
|
Yan KH, Lee LM, Yan SH, Huang HC, Li CC,
Lin HT and Chen PS: Tomatidine inhibits invasion of human lung
adenocarcinoma cell A549 by reducing matrix metalloproteinases
expression. Chem Biol Interact. 203:580–587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tyzzer EE: Factors in the production and
growth of tumor metastases. J Med Res. 28:309–332.1.
1913.PubMed/NCBI
|
|
3
|
Demicheli R, Retsky MW, Hrushesky WJ, Baum
M and Gukas ID: The effects of surgery on tumor growth: a century
of investigations. Ann Oncol. 19:1821–1828. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allen-Mersh TG, McCullough TK, Patel H,
Wharton RQ, Glover C and Jonas SK: Role of circulating tumour cells
in predicting recurrence after excision of primary colorectal
carcinoma. Br J Surg. 94:96–105. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cassinello F, Prieto I, del Olmo M, Rivas
S and Strichartz GR: Cancer surgery: How may anesthesia influence
outcome? J Clin Anesth. 27:262–272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu KC, Yang ST, Hsia TC, Yang JS, Chiou
SM, Lu CC, Wu RS and Chung JG: Suppression of cell invasion and
migration by propofol are involved in down-regulating matrix
metalloproteinase-2 and p38 MAPK signaling in A549 human lung
adenocarcinoma epithelial cells. Anticancer Res. 32:4833–4842.
2012.PubMed/NCBI
|
|
7
|
Song J, Shen Y, Zhang J and Lian Q: Mini
profile of potential anticancer properties of propofol. PLoS One.
9:e1144402014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kobayashi H, Shinohara H, Takeuchi K, Itoh
M, Fujie M, Saitoh M and Terao T: Inhibition of the soluble and the
tumor cell receptor-bound plasmin by urinary trypsin inhibitor and
subsequent effects on tumor cell invasion and metastasis. Cancer
Res. 54:844–849. 1994.PubMed/NCBI
|
|
9
|
Kobayashi H, Gotoh J, Fujie M and Terao T:
Characterization of the cellular binding site for the urinary
trypsin inhibitor. J Biol Chem. 269:20642–20647. 1994.PubMed/NCBI
|
|
10
|
Kobayashi H, Gotoh J, Kanayama N,
Hirashima Y, Terao T and Sugino D: Inhibition of tumor cell
invasion through matrigel by a peptide derived from the domain II
region in urinary trypsin inhibition. Cancer Res. 55:1847–1852.
1995.PubMed/NCBI
|
|
11
|
Kobayashi H, Shinohara H, Fujie M, Gotoh
J, Itoh M, Takeuchi K and Terao T: Inhibition of metastasis of
Lewis lung carcinoma by urinary trypsin inhibitor in experimental
and spontaneous metastasis models. Int J Cancer. 63:455–462. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kobayashi H: Mechanism of tumor
cell-induced extracellular matrix degradation-inhibition of
cell-surface proteolytic activity might have a therapeutic effect
on tumor cell invasion and metastasis. Nihon Sanka Fujinka Gakkai
zasshi. 48:623–632. 1996.(In Japanese). PubMed/NCBI
|
|
13
|
Yoshioka I, Tsuchiya Y, Aozuka Y, Onishi
Y, Sakurai H, Koizumi K, Tsukada K and Saiki I: Urinary trypsin
inhibitor suppresses surgical stress-facilitated lung metastasis of
murine colon 26-L5 carcinoma cells. Anticancer Res. 25:815–820.
2005.PubMed/NCBI
|
|
14
|
Kobayashi H, Shinohara H, Gotoh J, Fujie
M, Fujishiro S and Terao T: Anti-metastatic therapy by urinary
trypsin inhibitor in combination with an anti-cancer agent. Br J
Cancer. 72:1131–1137. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song B, Bian Q, Shao CH, Li G, Liu AA,
Jing W, Liu R, Zhang YJ, Zhou YQ, Hu XG and Jin G: Ulinastatin
reduces the resistance of liver cancer cells to epirubicin by
inhibiting autophagy. PLoS One. 10:e01206942015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao F, Sun Z, Sun X, Zhang Y, Wang H,
Zhong B, Luo J and Zhao X: Ulinastatin exerts synergistic effects
with taxotere and inhibits invasion and metastasis of breast cancer
by blocking angiogenesis and the epithelial-mesenchymal transition.
Cancer Biother Radiopharm. 28:218–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan SM: Postperfusion lung syndrome:
Respiratory mechanics, respiratory indices and biomarkers. Ann
Thorac Med. 10:151–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu HL and Qian YN: Protective effects of
propofol combined with ulinastatin on acute lung injury induced by
endotoxin in rats. Zhongguo Ying Yong Sheng Li Xue Za Zhi.
29:56–57. 622013.(In Chinese). PubMed/NCBI
|
|
19
|
Vinodhkumar R, Song YS, Ravikumar V,
Ramakrishnan G and Devaki T: Depsipeptide a histone deacetlyase
inhibitor down regulates levels of matrix metalloproteinases 2 and
9 mRNA and protein expressions in lung cancer cells (A549). Chem
Biol Interact. 165:220–229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ashton JC: Drug combination studies and
their synergy quantification using the Chou-Talalay method-letter.
Cancer Res. 75:24002015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yousef BA, Hassan HM, Guerram M, Hamdi AM,
Wang B, Zhang LY and Jiang ZZ: Pristimerin inhibits proliferation,
migration and invasion, and induces apoptosis in HCT-116 colorectal
cancer cells. Biomed Pharmacother. 79:112–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Page GG: Surgery-induced immunosuppression
and postoperative pain management. AACN Clin Issues. 16:302–309;
quiz 416–418. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Granov AM, Rozenberg OA, Tsybul'kin EK,
Erokhin VV, Khubulava GG, Likhvantsev VV, Osovskikh VV, Bautin AE,
Gavrilin SV, Kazennov VV, et al: Critical state medicine.
Surfactant therapy of adult respiratory distress syndrome (results
of multicenter studies). Vestn Ross Akad Med Nauk. 34–38. 2001.(In
Russian). PubMed/NCBI
|
|
25
|
Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y and
Wang YL: A comparison of the effect of total intravenous
anaesthesia with propofol and remifentanil and inhalational
anaesthesia with isoflurane on the release of pro- and
anti-inflammatory cytokines in patients undergoing open
cholecystectomy. Anaesth Intensive Care. 36:74–78. 2008.PubMed/NCBI
|
|
26
|
Kushida A, Inada T and Shingu K:
Enhancement of antitumor immunity after propofol treatment in mice.
Immunopharmacol Immunotoxicol. 29:477–486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou W, Fontenot HJ, Wang SN and Kennedy
RH: Propofol-induced alterations in myocardial beta-adrenoceptor
binding and responsiveness. Anesth Analg. 89:604–608. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
González-Correa JA, Cruz-Andreotti E,
Arrebola MM, López-Villodres JA, Jódar M and De La Cruz JP: Effects
of propofol on the leukocyte nitric oxide pathway: In vitro and ex
vivo studies in surgical patients. Naunyn Schmiedebergs Arch
Pharmacol. 376:331–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hosokawa T, Hori Y, Nakagawa H, Nakagawa
M, Hashimoto T and Miyazaki M: Effect of urinastatin on immunity
during anesthesia and surgery for malignant disease. Masui.
38:1341–1348. 1989.PubMed/NCBI
|
|
30
|
Guzmán-Mejía F, López-Rubalcava C and
González-Espinosa C: Stimulation of nAchRα7 receptor inhibits TNF
synthesis and secretion in response to LPS treatment of mast cells
by targeting ERK1/2 and TACE activation. J Neuroimmune Pharmacol.
13:39–52. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mezzasoma L, Antognelli C and Talesa VN: A
novel role for brain natriuretic peptide: Inhibition of IL-1β
secretion via downregulation of NF-kB/Erk 1/2 and
NALP3/ASC/caspase-1 activation in human THP-1 monocyte. Mediators
Inflamm. 2017:58583152017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Al-Ejeh F, Kumar R, Wiegmans A, Lakhani
SR, Brown MP and Khanna KK: Harnessing the complexity of DNA-damage
response pathways to improve cancer treatment outcomes. Oncogene.
29:6085–6098. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Okumura E, Fukuhara T, Yoshida H, Hanada
Si S, Kozutsumi R, Mori M, Tachibana K and Kishimoto T: Akt
inhibits Myt1 in the signalling pathway that leads to meiotic
G2/M-phase transition. Nat Cell Biol. 4:111–116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yan Y, Black CP and Cowan KH:
Irradiation-induced G2/M checkpoint response requires ERK1/2
activation. Oncogene. 26:4689–4698. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cristea S and Sage J: Is the canonical
RAF/MEK/ERK signaling pathway a therapeutic target in SCLC? J
Thorac Oncol. 11:1233–1241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Frémin C, Saba-El-Leil MK, Lévesque K, Ang
SL and Meloche S: Functional redundancy of ERK1 and ERK2 MAP
kinases during development. Cell Rep. 12:913–921. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fey D, Matallanas D, Rauch J, Rukhlenko OS
and Kholodenko BN: The complexities and versatility of the
RAS-to-ERK signalling system in normal and cancer cells. Semin Cell
Dev Biol. 58:96–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Persaud SD, Park SW, Ishigami-Yuasa M,
Koyano-Nakagawa N, Kagechika H and Wei LN: All trans-retinoic acid
analogs promote cancer cell apoptosis through non-genomic Crabp1
mediating ERK1/2 phosphorylation. Sci Rep. 6:223962016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee SH, Jaganath IB, Manikam R and Sekaran
SD: Inhibition of Raf-MEK-ERK and hypoxia pathways by Phyllanthus
prevents metastasis in human lung (A549) cancer cell line. BMC
Complement Altern Med. 13:2712013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Okumichi T, Nishiki M, Takasugi S, Toki N
and Ezaki H: Isolation of urinary trypsin inhibitor-like inhibitor
from human lung cancer tissue. Cancer Res. 44:2011–2015.
1984.PubMed/NCBI
|
